Nordic Stars Award is a prize highlighting early and exciting Nordic life science companies. It was established in 2013 with the purpose of rewarding particularly innovative companies belonging to the Nordic life science community contributing for the benefit of patients, industry and society alike.
Nordic Life Science Days has become an established arena for high quality meetings between investors, global life science companies and Nordic innovations. It has grown rapidly to become the largest annual Life Science Invest and Partnering meeting in the Nordic region with nearly 700 companies represented in the activities with the number of delegates approaching 1100.
– The price is not only a recognition of our dedicated efforts in the vaccine field, says Michael Wolff Jensen, Chairman of the Board of Eurocine Vaccines. The award also acknowledges the importance of addressing unmet medical needs and thereby improving quality of life for patients and their families, Mr. Wolff Jensen concludes.
Eurocine Vaccines will soon enter clinical trials with their nasal quadrivalent influenza vaccine particularly aimed for children under the age of 2 years. Based on their proprietary adjuvant technology, the company is targeting a patient population where current vaccines have low preventive effects and recommendations from authorities world-wide are likely to result in a growing market. A vaccine without a needle could no doubt be labelled patient centric!”
NLSD and SwedenBIO
For more information, please contact:
Hans Arwidsson, Ph.D., MBA
CEO of Eurocine Vaccines
Mobile: +46 70 634 0171.
Press Release from NLSD – Winners of Nordic Stars Award 2016
Article in Life Science Sweden – De är årets nordiska stjärnor (Swedish)
Nordic Life Science Days, NLSD
About Eurocine Vaccines
Eurocine Vaccines is a publicly listed company, using its clinically validated technology Endocine™ to develop a patent protected nasal influenza vaccine for children. Within the market for influenza vaccines, children is the fastest growing segment. This is due to the recommendation by the WHO to vaccinate children against influenza. The company´s main project, the nasal quadrivalent influenza vaccine Immunose™ FLU, is planned to enter clinical development in the fall of 2016.
The company plans to license the product to partners for further development and commercialization.
Eurocine Vaccines, EUCI, is traded at Aktietorget, XSAT.